Replagal is named as an intervention in 2 current clinical trials in our UK, USA, China, Germany, France, Spain, Italy, Netherlands, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Japan, South Korea, Taiwan and India registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Sanofi (1). The most-studied condition is Fabry Disease.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Replagal in Children and Adults With Fabry Disease in India
NCT05067868 · ClinicalTrials.gov ↗ · Fabry Disease
|
Phase 4 | Recruiting | Shire | India |
|
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT05280548 · ClinicalTrials.gov ↗ · Fabry Disease
|
Phase 3 | Active, closed | Sanofi | UK, USA, China, Germany, France, Spain, Italy, Netherlands, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Japan, South Korea, Taiwan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Sanofi | 1 |
| Shire | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK, USA, China, Germany, France, Spain, Italy, Netherlands, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Japan, South Korea, Taiwan and India registers name Replagal as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Sanofi (1) and Shire (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Replagal works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Replagal works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Replagal (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.